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Abstract
Purpose In pulmonary hypertension (PH), hypoxia represents both an outcome and a cause of exacerbation.We addressed the question
whether hypoxia adaptation might affect the mechanisms underlying PH alleviation through phosphodiesterase-5 (PDE5) inhibition.
Methods Eight-week-old male Sprague-Dawley rats were divided into two groups depending on treatment (placebo or sildenafil,
a drug inhibiting PDE5) and were exposed to hypoxia (10% O2) for 0 (t0, n = 9/10), 2 (t2, n = 5/5) or 4 (t4, n = 5/5) weeks. The
rats were treated (0.3 mL i.p.) with either saline or sildenafil (1.4 mg/Kg per day).
Results Two-week hypoxia changed the body weight (− 31% vs. − 27%, respectively, P = NS), blood hemoglobin (+ 25% vs. +
27%, P = NS) and nitrates+nitrites (+ 175% vs. + 261%, P = 0.007), right ventricle fibrosis (+ 814% vs. + 317%, P < 0.0001),
right ventricle hypertrophy (+ 84% vs. + 49%,P = 0.007) and systolic pressure (+ 108% vs. + 41%, P = 0.001), pulmonary vessel
density (+ 61% vs. + 46%, P = NS), and the frequency of small (< 50 µmwall thickness) vessels (+ 35% vs. + 13%, P = 0.0001).
Most of these changes were maintained for 4-week hypoxia, except blood hemoglobin and right ventricle hypertrophy that
continued increasing (+ 52% vs. + 42%, P = NS; and + 104% vs. + 83%, P = 0.04). To further assess these observations, small
vessel frequency was found to be linearly related with the right ventricle-developed pressure independent of hypoxia duration.
Conclusions Thus, although hypoxia adaptation is not yet accomplished after 4 weeks, PH alleviation by PDE5 inhibition might
nevertheless provide an efficient strategy for the management of this disease.
Keywords Chronic hypoxia . Adaptation . Phosphodiesterase-5 inhibition . Pulmonary angiogenesis . Right-ventricle
hypertrophy
Introduction
The pathophysiology of pulmonary hypertension (PH) includes
progressive rising of the pulmonary artery pressure, with sub-
sequent straining of the right ventricle (RV) thereby causing
hypertrophy and leading to potential right heart failure and/or
ventricular arrhythmias. In addition to the fact that PH contrib-
utes to the impairment of the pulmonary function with subse-
quent deterioration of the gas exchange, thereby causing sys-
temic hypoxia, hypoxia per se also represents one of the main
complications of PH, establishing an irreversible vicious circle,
whereby PH causes hypoxia, which in turn exacerbates PH [1].
Healthy individuals, however, may in part compensate systemic
hypoxia through adaptation, a complex phenomenon recruiting
the pulmonary, cardiovascular, hematological, metabolic, and
endocrine systems [2, 3]. Is the mechanism of hypoxia adapta-
tion also applicable in patients with PH, caused either by con-
genital heart defects or by acquired diseases? This question
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might be relevant because a therapy proven to be effective in
the treatment of PH, e.g., phosphodiesterase-5 (PDE5) inhibi-
tion by sildenafil [4, 5], generally used as a vasodilator agent to
antagonize the vasoconstriction present in pulmonary hyperten-
sion, could be extended to treat also the negative effects of
pulmonary hypertension such as subsequent hypoxia.
Therefore, it is important to assess whether PH-induced hypox-
ia is also responding to adaptation. Remarkably, while studies
have been reported on the long-term effects in the pediatric
population with PH [6–9], evidence for similar long-term ben-
eficial effects of PDE5 inhibitors in COPD patients is still con-
troversial [10–12], thereby justifying experimental studies
aiming to answer the question whether the effects of hypoxia,
and hence of PDE5 inhibition, are time-dependent.
The design of the present study was focused on assessing if
some of the mechanisms known to underlie alleviation of
hypoxia-induced PH by PDE5 inhibition [13] are time-depen-
dent. Such information might be important not only to confirm
the viability of themechanisms for a better treatment of hypoxia
of longer duration but also to assess whether other time-
dependent mechanisms, potentially linked to hypoxia adapta-
tion, may eventually override the protection afforded by silden-
afil and introduce bias in the interpretation of results. Therefore,
the target of this study was to test whether the cardiopulmonary
dysfunction caused by hypoxia and the correction provided by
sildenafil display time-dependent features. To this purpose, we
examined two time durations (2 and 4 weeks) of challenge
(hypoxia) and treatment (sildenafil).
Methods
Protocol
We used male 8-week old Sprague-Dawley rats (200–250 g
initial nominal weight). Rats were randomly divided into two
groups depending on treatment (without/with sildenafil) and
were exposed to hypoxia (10% O2) as described previously
[13] for 0 (t0, n = 9/10), 2 (t2, n = 5/5), or 4 (t4, n = 5/5) weeks.
Rats were treated (0.3 mL i.p.) with either saline or sildenafil
(1.4 mg/kg/day). Treatments started in correspondence to ex-
posure to hypoxia.
Twenty-four hours after the last treatment, rats were anes-
thetized (80 mg/kg xylazine, 100 mg/kg ketasol, and 1500 IU
heparin i.p.) in the compensation chamber at 10% O2.
To assess the hemodynamics, anesthetized rats were placed
on a heating pad at 37 °C and ventilated at 50 cycles min−1
(tidal volume of 2.5 mL, Harvard Apparatus model 683,
Holliston, MA, USA) with either room air (21% O2) or hyp-
oxic (10% O2) atmosphere for normoxic and hypoxic groups,
respectively. To evaluate the LV pressures, a Millar catheter
was introduced into the LV via the right carotid artery. To
evaluate RV pressures, the chest cavity was opened and
Millar catheter was directly introduced in the RV cavity using
a 24-gauge needle, and connected to a MPVS Ultra system
(Millar Instruments) to record the pressure waves. At the end
of hemodynamic analysis, lungs and hearts were perfused en-
block with PBS via the RV with efflux through a small open-
ing in the left atrium [14], placed in PBS and kept on ice. Atria
were removed, the RVand the septum (S) were isolated, blot-
ted dry and weighed to obtain the RV/(LV + S) ratio.
Pulmonary Vascular Remodeling
The degree of muscularization of pulmonary arterioles was
assessed from immunohistochemical staining of the small pul-
monary artery, as previously described [13]. Briefly, the lungs
were inflated with 10% formalin at 25 cm H2O pressure
through the trachea for 15 min, excised and finally processed
for paraffin embedding. Paraffin-embedded lungs were serial-
ly sectioned at 8-μm thickness. Following citrate-based anti-
gen retrieval, the sections were blocked with 5% (v/v) goat
serum for 1 h. Then, sections were incubated with an antibody
against smooth muscle α-actin (α-SMA 1:250, clone 1A4,
Sigma-Aldrich) overnight at 4 °C, followed by a goat anti-
mouse IgG secondary antibody (1/500, DAKO), developed
with 3,3′-diaminobenzidine, and counter stained with hema-
toxylin and eosin. All transversal cut arterioles were quantita-
tively analyzed at × 40magnification using an images analysis
system Nikon eclipse 80i camera and NIH image software
(Nikon Instruments Inc., Melville, NY, USA). Pulmonary ar-
terial thickening was assessed by calculating the percent pul-
monary artery thickness using the following formula:
100 × (perivascular area-luminal area)/luminal area.
Pulmonary arteries were categorized as follows: < 50 μm,
50–100 μm, 100–200 μm, and > 200 μm. Ten vessels were
analyzed for each rat, in six rats per group per time-point.
Morphological analyses were conducted in a double-blind
method.
RV Fibrosis
RV fibrosis was evaluated by routine Masson’s staining. The
images were taken in random field at a magnification of × 200,
and the area of cardiac fibrosis was calculated by using NIH
image software.
Biochemical Measurements
StandardWestern blotting analysis was performed in lung and
cardiac lysates [14] using antibodies against p-eNOS (Ser1177,
1:1000, Cell Signaling Technology) and e-NOS (1:1000,
Santa Cruz Biotechnology, Santa Cruz). Secondary HRP-
conjugated antibodies were applied for 1 h at room tempera-
ture, and signals were detected by using the enhanced chemi-
luminescence system (Amersham, Arlington Heights, IL,
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USA) of a commercial ECL kit. Quantification of the band
intensities was performed using NIH ImageJ.
Blood hemoglobin (Hb, Drabkin’s reagent) and plasma ni-
trates and nitrites (NOx, colorimetric Griess reaction) were
measured in heparinized samples taken after euthanasia.
Statistics
Data are expressed as mean ± SEM. To measure the effect of
hypoxia duration, we performed one-way analysis of variance
followed by the Bonferroni test to detect significant differ-
ences between the time points. To measure the differences
between the two treatments at every time point, we used the
unpaired t test. The significance level was set at P = 0.05.
Results
All the animals used in this study survived the protocols.
Hypoxia markedly decreased the body weight at t2
irrespectively of sildenafil treatment (P < 0.05 vs. t0 for both
control and sildenafil, Fig. 1). This change was maintained at
t4 (P =NS vs. t2 in both groups). A slight favorable effect of
sildenafil was, however, noticed at t4 (P = 0.046). Hypoxia
steadily increased blood [Hb] at both t2 (P < 0.05 vs. t = 0) and
t4 (P < 0.05 vs. t = 2 weeks). A slight borderline effect of
sildenafil was observed at t4 (P = 0.052).
At t2, the heart/body weight ratio increased by 60% in
controls (P < 0.05 vs. t0) and did not change further at t4
(P =NS vs. t = 2 weeks), indicating no increase in myocardial
hypertrophy after 2-week hypoxia. Sildenafil halved the pro-
gression of myocardial hypertrophy at both times (P = 0.0035
and P < 0.00001 vs. control at t2 and t4, respectively). To
follow up the effect on RV hypertrophy, we used the RV/
(LV + S) ratio. This index increased markedly at t2 (P < 0.05
vs. t0 for both control and sildenafil), but the increase was less
marked in sildenafil than controls (P = 0.007). At t4, the RV/
(LV + S) ratio did not change appreciably in control hearts
(P =NS vs. t2) but increased significantly in sildenafil hearts
(P < 0.05 vs t2). Consequently, the difference between control
and sildenafil decreased but remained significant (P = 0.046).
Two-week hypoxia augmented the vessel density in both
the right and left lungs (only the left lung is shown for clarity,
P < 0.05 vs. t0). Only a borderline (P = 0.058) effect of
Fig. 1 Effects of various durations of hypoxia in the absence (filled
circles) and in the presence (empty squares) of sildenafil (1.4 mg/kg/
day). The vertical bars represent the SEM. Sildenafil data points are
slightly nudged to the right to enable distinguishing overlapping
symbols and error bars. $,§P < 0.05 (ANOVA and Bonferroni tests)
with respect to t0 and t2, respectively. *P < 0.05 (unpaired Student’s t
test) between control and sildenafil groups for each time point
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sildenafil was observed. At t4, the vessel density did not
change appreciably vs. t2, but the anti-angiogenic effect of
sildenafil became very clear (P < 0.0001).
Figure 2 shows several hemodynamic parameters. The LV
systolic pressure remained unaffected by hypoxia (P =NS vs.
t0) and sildenafil (P =NS). By contrast, the RV systolic pressure
nearly doubled at t2 in controls (P < 0.05 vs. t0), indicative of
PH, with no change at t4. In sildenafil rats at t2, the raise in RV
systolic pressure was markedly less (+ 41% vs. + 108% in con-
trols, P = 0.0014) and was maintained at t4 (+ 40% vs. + 97%,
P = 0.002). The end-diastolic pressure did not change apprecia-
bly at t2, but it increased significantly at t4. The increase was +
377% (P < 0.0001) and + 147% (P = 0.02) in control and silden-
afil rats, respectively, with a highly significant difference be-
tween the two groups (P = 0.007). By contrast, + dP/dtmax and
− dP/dtmax were significantly increased + 50–70% at t2 in both
groupswith no significant difference. At t4, sildenafil blunted the
increase in + dP/dtmax vs. no significant effects in − dP/dtmax.
Figure 3 shows the frequency of lung vessels belonging to
four categories of wall thickness, arbitrarily divided into small
(0–50 μm), medium (50–100 μm), large (100–200 μm), and
very large (> 200 μm). Because data from right lungs are
indistinguishable from those from left lungs (not shown), for
clarity, we report only data from left lungs. It appears that the
effect of 2-week hypoxia was much pronounced for small
vessels and progressively diminished for increasing vessel
diameter. For example, the number of vessels in the 0–
50 μm range increased by 35% vs. 11% for 50–100 μm, and
near zero for larger vessels. As a result, the effect of sildenafil
was more marked in small than in large vessels, 13% in the 0–
50 μm range (P < 0.0001 vs. control) and virtually zero for
larger vessels. In no case, however, was there a difference
between t2 and t4, indicating a stable situation.
Figure 4 shows indexes of RV fibrosis obtained as ex-
plained in the BMethods^ section. While hypoxia increased
fibrosis (P < 0.0001), the increase was markedly more pro-
nounced in control vs. sildenafil rats (P = 0.007 and
0.0005 at t2 and t4, respectively), indicating that sildenafil
has a strong anti-fibrotic effect in this model.
Figure 5 shows that the p-eNOS/eNOS ratio highlights the
activation of endothelium NO-producing enzymes in the heart
and in the lung. In both cases, 2-week hypoxia decreased the
p-eNOS/eNOS ratio in control (P < 0.05), as opposite to con-
stant and increased p-eNOS/eNOS ratio in sildenafil-treated
hearts (P = 0.01) and lungs (P < 0.0001), respectively. At t4,
the situation remained stable, highlighting a protective effect
of sildenafil in both tissues independent of hypoxia duration.
Plasma NOx concentration marks the blood NO storage
level. Two-week hypoxia increased thismarker in both control
and sildenafil rats (P < 0.05 vs. t0), but in sildenafil-treated
rats, this effect was higher (P = 0.007). The situation did not
change appreciably at t4.
To further assess the effects observed above, Fig. 6
shows the relationship between the frequency of small
vessels (0–50 μm) and the pressure developed by LV (up-
per panel) and RV (lower panel). As far as the LV is
Fig. 2 Hemodynamic
parameters. Effects of various
durations of hypoxia in the
absence (filled circles) and in the
presence (empty squares) of
sildenafil (1.4 mg/kg/day). The
vertical bars represent the SEM.
Sildenafil data points are slightly
nudged to the right to enable
distinguishing overlapping
symbols and error bars. $,§P <
0.05 (ANOVA and Bonferroni
tests) with respect to t0 and t2,
respectively. *P < 0.05 (unpaired
Student’s t test) between control
and sildenafil groups for each
time point
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concerned, the slope of the best-fit line (− 1.357 ± 0.9287)
did not differ from zero (P = NS). However, the best-fit
slope increased markedly to + 2.352 ± 0.2563 (P < 0.0001
vs. zero) in the RV. Of interest, the relationship between
the RV systolic pressure and the small vessels frequency
was independent of hypoxia duration, indicating that the
treatment with sildenafil could reduce the RV systolic
pressure for both time durations.
Fig. 3 Effects of various durations of hypoxia in the absence (filled
circles) and in the presence (empty squares) of sildenafil (1.4 mg/kg/
day). The vertical bars represent the SEM. Sildenafil data points are
slightly nudged to the right to enable distinguishing overlapping
symbols and error bars. $,§P < 0.05 (ANOVA and Bonferroni tests)
with respect to t0 and t2, respectively. *P < 0.05 (unpaired Student’s t
test) between control and sildenafil groups for each time point. The
microphotographs show representative examples of the Masson’s
staining to evaluate lung tissue fibrosis in the various cases considered
in this study
Fig. 4 Effects of various durations of hypoxia in the absence (filled
circles) and in the presence (empty squares) of sildenafil (1.4 mg/kg/
day) on RV cardiac fibrosis. The vertical bars represent the SEM.
Sildenafil data points are slightly nudged to the right to enable
distinguishing overlapping symbols and error bars. $,§P < 0.05
(ANOVA and Bonferroni tests) with respect to t0 and t2, respectively.
*P < 0.05 (unpaired Student’s t test) between control and sildenafil
groups for each time point. The microphotographs show representative
examples of the Masson’s staining to evaluate tissue fibrosis in the
various cases considered in this study
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Discussion
In our observations, 2- and 4-week duration of hypoxia in-
duced relevant non-lethal cell and molecular alterations. As
expected, hypoxia impaired the homeostasis and increased
blood [Hb] and NOx, and increased the degree of RV hyper-
trophy, the extent of pulmonary angiogenesis, the total num-
ber of small vessels in the lungs, and the values of RV systolic
pressures, without any direct or secondary influence on LV
pressures. Most, but not all of these changes, occur within
2 weeks and are essentially maintained unchanged at the 4-
week interval. However, some of the variables investigated,
including blood [Hb] and RV hypertrophy, continue to change
with the extension of the duration of hypoxia from 2 to
4 weeks. Whereas augmenting [Hb] reflects a situation of
ongoing hypoxia without complete adaptation, increased RV
hypertrophy reflects the long-term morphological effects of
pro-angiogenic and proliferative factors engaged during the
first 2 weeks of hypoxia. Thus, although adaptation seems to
be a process not yet completely accomplished after 4-week
hypoxia, most of the myocardial and pulmonary responses to
hypoxia are independent from the total process of adaptation.
NO handling is of critical relevance because NO controls
myriads of cell/molecular pathways relevant for heart and
lung viability. For example, RV hypertrophy without lung
hypertrophy, as well as the raise of RV pressure, without ef-
fects on LV pressure, has been associated with increased e-
NOS phosphorylation in both hearts and lungs, and increased
plasma NOx levels [13]. Remarkable blunting of all these
features through PDE5 inhibition by sildenafil represents a
solid proof-of-concept for the employment of this drug to
alleviate symptoms in several cardiopulmonary diseases in-
cluding PH [4] and to correct hypoxia-induced RV hypertro-
phy [1]. This scenario reflects a situation where sildenafil-
induced increase in cGMP levels upregulates eNOS phos-
phorylation [15–20], and hence plasma NOx, which translates
into cardiomyocyte apoptosis mitigation. In addition to its
usefulness to treat heart failure without remarkable adverse
Fig. 5 Effects of various durations of hypoxia in the absence (filled
circles) and in the presence (empty squares) of sildenafil (1.4 mg/kg/
day). The vertical bars represent the SEM. Sildenafil data points are
slightly nudged to the right to enable distinguishing overlapping
symbols and error bars. $,§P < 0.05 (ANOVA and Bonferroni tests)
with respect to t0 and t2, respectively. *P < 0.05 (unpaired Student’s t
test) between control and sildenafil groups for each time point.
Representative Western blots are shown
Fig. 6 Relationship between the frequency of small diameter vessels (0–
50 μm) and the pressure developed by the left (upper panel) and right
(lower panel) ventricle for each experimental data point. Empty and filled
symbols refer to rats treated with placebo and sildenafil, respectively.
Triangles, squares, and circles represent data taken at t0, t2, and t4,
respectively. The best-fit lines and the 95% confidence limits referring
to all available data points are shown. The values of the slope are − 1.357
± 0.9287 and + 2.352 ± 0.2563 for the left and right ventricle, respectively
(P =NS and P < 0.0001 vs. zero)
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effects [21], sildenafil may also have effects not only neces-
sarily linked to vasodilation, as for example increased recruit-
ment of bonemarrow-derived c-kit+ cells with amelioration of
pulmonary hemodynamic [14]. These mechanisms, however,
have been studied within a single 2-week hypoxia situation,
and there are no clues to ascertain whether such mechanisms
reflect a transient situation or remain constant overtime [1]. In
this study, we demonstrate that most of the underlying mech-
anisms are essentially unaffected by the duration of hypoxia
and thus reflect a stable condition, independent from hypoxia
adaptation. This is supported by the observation that the
values of the pulmonary artery pressures in healthy high-
landers increase in correlation with altitude and with the de-
gree of exercise, and are related with a delayed postnatal re-
modeling of the distal pulmonary arterial branches [22].
The entity of the distribution of the vessels within the lungs
is markedly depending on the diameter of the vessels. While
the size of the small pulmonary vessels is affected by the
degree of hypoxia and by sildenafil administration, the effects
of both hypoxia and sildenafil are progressively diminishing
in correlation with the size of the vessels. If we accept that the
size of the vessel is associated with their degree of maturation,
then this effect may be attributed to their maturation process.
Although there is still disagreement about the molecular trig-
ger of such process, the degree of phosphorylation of eNOS is
most probably an important mediator; its persistent increase
after 2 and 4 weeks of hypoxia in both the myocardial and
pulmonary tissues of the sildenafil-treated rats reflects the an-
giogenic stimulus caused by hypoxia and the persistent cor-
rection of this stimulus by sildenafil.
The response to sildenafil, evident at both t2 and t4, can be
considered to be due to the combination of the indirect effects
on the RV function as a consequence of reduced afterload
secondary to reduced pulmonary vascular resistance, as well
as of the direct effect on the RV diastolic function. Whereas
the effect of the afterload reduction was already well
established [23], the capability of sildenafil to improve RV
diastolic function was also previously reported in the presence
of fixed afterload increase, such as that obtained by pulmonary
artery banding [24]. This double action of sildenafil was
confirmed by our observations, with the RV hemodynamics
improved by sildenafil despite the presence of RV fibrosis at
both t2 and t4.
With regard to the correlation between RV function and
fibrosis, topic of controversies in the recent literature, it is
important to evaluate presence, degree and distribution of fi-
brosis in the RV, as well as the duration of fibrosis. All these
can influence not only RV systolic function, as generally stud-
ied and reported, but also diastolic function. Our observations,
for instance, have proven the positive effects of sildenafil on
RV diastolic function, regardless of the associated effects of
the pulmonary vascular resistance, because the degree and
distribution of RV fibrosis remained unchanged after 2 and
4 weeks. Masson staining is a reliable procedure to evaluate
RV fibrosis [25]. The results shown in Figs. 2 and 4 are in
essential agreement with a recent report that, although RV
fibrosis is clearly linked to RV dysfunction, reduction of RV
fibrosis does not directly improve cardiac function [26].
Limits of the study
As a consequence of the design of our study, the treatment
with sildenafil was started simultaneously with the induction
of chronic hypoxia, and we are fully aware of the potential
criticism of missing the evaluation of the potential effects of
sildenafil after establishing chronic hypoxia. On the other
hand, the effects of sildenafil on pulmonary hypertension per
se are well acknowledged. Moreover, the RV diastolic pres-
sures, which could provide useful information in order to
correlate the values of RV end-diastolic pressure with the de-
gree of RV hypertrophy and/or of PH, were not recorded in
this study because of logistic reasons.
In this study, sildenafil was not compared with other pul-
monary vasodilator drugs which recently have appeared on
the market, because our aim was to specifically evaluate the
effects of sildenafil, without adding other confounding factors.
Conclusions
Sildenafil provides an efficient strategy for the management of
RV hypertrophy, PH, and pulmonary remodeling, thanks to its
effects on the pulmonary vasculature, facilitating improve-
ment of the RV function, irrespectively of hypoxia adaptation.
This finding suggests that sildefanil potentially could be used
in the management of clinical settings characterized by pul-
monary hypertension complicated by subsequent chronic hyp-
oxia, as in PH secondary to congenital heart defects or ac-
quired lung issues with chronic obstructive disease.
Prospective randomized clinical trials are required to verify
the applicability of this therapeutic strategy in patients.
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